Xgeva: osteoclast-targeting agent for malignant fractures

Xgeva (denosumab) has been launched for the prevention of skeletal events due to bone metastases from solid tumours.

Subcutaneous injection to prevent skeletal events
Subcutaneous injection to prevent skeletal events

Denosumab is a fully human monoclonal antibody specific for the RANK ligand, which is essential for the differentiation, function and survival of osteoclasts. Denosumab is already licensed as Prolia to treat bone loss in postmenopausal women and in men with prostate cancer.

Three randomised, double-blind studies assessed the capacity of denosumab, given as a 120mg subcutaneous injection every four weeks, to prevent events such as pathological fracture and spinal cord compression in 5723 patients with advanced malignancies. The studies enrolled patients with breast cancer, prostate cancer, and other solid tumours or multiple myeloma.

Compared with zoledronic acid, denosumab increased the median time to the first skeletal-related event by 8.2 months (from 19.4 months to 27.6 months; p<0.0001). Overall survival and time to pain improvement were similar for the two agents.

View Xgeva drug record

Further Information: Amgen

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases